Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Dec
20
Today In Oncology
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
Data Published on Incidence of Immune Checkpoint Inhibitor-Associated ITP
Lymphocyte Kinetics After CAR T Infusion Predict Survival Outcomes in Non-Hodgkin Lymphoma
CD123-Targeting ADC Shows Activity in AML and BPDCN
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo